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Abstract
Vacuolar protein sorting 41 (VPS41) is as part of the Homotypic
fusion and Protein Sorting (HOPS) complex required for lysosomal
fusion events and, independent of HOPS, for regulated secretion.
Here, we report three patients with compound heterozygous
mutations in VPS41 (VPS41S285P and VPS41R662*; VPS41c.1423-2A>G
and VPS41R662*) displaying neurodegeneration with ataxia and
dystonia. Cellular consequences were investigated in patient
fibroblasts and VPS41-depleted HeLa cells. All mutants prevented
formation of a functional HOPS complex, causing delayed lysoso-
mal delivery of endocytic and autophagic cargo. By contrast,
VPS41S285P enabled regulated secretion. Strikingly, loss of VPS41
function caused a cytosolic redistribution of mTORC1, continuous
nuclear localization of Transcription Factor E3 (TFE3), enhanced
levels of LC3II, and a reduced autophagic response to nutrient
starvation. Phosphorylation of mTORC1 substrates S6K1 and 4EBP1
was not affected. In a C. elegans model of Parkinson’s disease, co-
expression of VPS41S285P/VPS41R662* abolished the neuroprotective
function of VPS41 against a-synuclein aggregates. We conclude
that the VPS41 variants specifically abrogate HOPS function, which
interferes with the TFEB/TFE3 axis of mTORC1 signaling, and cause
a neurodegenerative disease.
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Introduction
While lysosomes are responsible for the degradation and recycling
of intra- and extracellular substrates (Saftig & Klumperman, 2009),
they are increasingly recognized as regulators of cellular homeo-
stasis and key players in nutrient sensing and transcriptional
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regulation (Luzio et al, 2007; Richardson et al, 2010; Settembre et
al, 2015; Mony et al, 2016). Hence, the digestive properties of lyso-
somes provide them with a major role in the control of cellular
metabolism and nutrient homeostasis. To accomplish this, HOPS
(Homotypic Fusion and Protein Sorting), a multisubunit tethering
complex, regulates fusion of lysosomes with endosomes and
autophagosomes (Seals et al, 2000; Wurmser et al, 2000; Caplan et
al, 2001; Pols et al, 2013a; Kant et al, 2015; Beek et al, 2019).
Vacuolar Protein Sorting 41 (VPS41) (VPS41, found on Chromo-
somal location; Chr7p14.1) is a defining component of HOPS, and a
100 kD protein that contains a WD40, TRP-like (tetratricopeptide
repeat), CHCR (Clathrin Heavy Chain Repeat), and RING (Really
Interesting New Gene)-H2 Zinc Finger domain (Radisky et al, 1997;
Nickerson et al, 2009). VPS41 knockout mice die early in utero,
signifying VPS41 as an essential protein for embryonic development
(Aoyama et al, 2012). HOPS-associated VPS41 is recruited to endo-
somes by binding to Rab7 and its interactor Rab interacting lysoso-
mal protein, and to lysosomes by interacting with Arf-like protein
8b (Arl8b; Lin et al, 2014; Khatter et al, 2015). Depletion of VPS41
impairs HOPS-dependent delivery of endocytic cargo to lysosomes
and causes a defect in autophagic flux (Takats et al, 2009; Pols et al,
2013a). Independent of HOPS, VPS41 is required for transport of
lysosomal membrane proteins from the trans-Golgi-Network (TGN)
to lysosomes (Swetha et al, 2011; Pols et al, 2013b), akin to the
Alkaline Phosphatase (ALP) pathway in yeast (Cowles et al, 1997a;
Rehling et al, 1999; Darsow et al, 2001; Angers & Merz, 2009; Cabr-
era et al, 2010). Furthermore, in secretory cells and neurons, VPS41
is required for regulated secretion of neuropeptides (Burgess &
Kelly, 1987; Orci et al, 1987; Tooze & Huttner, 1990; Eaton et al,
2000; Asensio et al, 2010; Asensio et al, 2013; Hummer et al, 2017).
Together, these data show that VPS41, as part of HOPS, is required
for lysosomal fusion events and, independent of HOPS, for transport
of lysosomal membrane proteins and regulated secretion.
Interestingly, VPS41 overexpression protects dopaminergic
neurons against neurodegeneration. This was shown in a transgenic
C. elegans model of Parkinson’s disease, in which a-synuclein is
locally overexpressed (Hamamichi et al, 2008; Ruan et al, 2010;
Harrington et al, 2012), and in human neuroglioma cells overex-
pressing a-synuclein (Harrington et al, 2012). Neuroprotection
against a-synuclein requires interaction of VPS41 with Rab7 and
adaptor protein-3 (AP-3) (Griffin et al, 2018). Recent studies in C.
elegans showed that overexpression of human VPS41 also mitigates
Ab-induced neurodegeneration of glutamatergic neurons. This
requires the small GTPase Arl8b rather than Rab7 or AP-3, indicat-
ing that VPS41, through different interaction partners, can trigger
divergent neuroprotective mechanisms against Parkinson’s disease
and Alzheimer’s disease (Griffin et al, 2018). However, how
VPS41’s function leads to neuroprotection remains to be elucidated.
Naturally occurring SNPs in VPS41 have been described (T52R,
T146P and A187T; Harrington et al, 2012; Ibarrola-Villava et al,
2015), and very recently a single patient with early onset dystonia
and a homozygous canonical splice site variant in VPS41 was identi-
fied (Steel et al, 2020). In this patient, cDNA studies demonstrated
that the variant leads to in-frame skipping of exon 7. In our current
study, we present three patients with severe neurological features
(e.g., ataxia and dystonia accompanied by retinal dystrophy and
mental retardation with brain MRI findings of cerebellar atrophy
and thin corpus callosum) of unknown etiology. Exome sequencing
showed that the patients were compound heterozygous for variants
in VPS41 [NM_014396.19: c.853T > C, NP_055211.2: p. Ser285Pro
(S285P); NM_014396.6: c.1984C > T, NP_055211.2: p. Arg662Stop
(R662*); NM_014396.3: c.1423-2A > G, r.(spl?)]. At the cellular
level, we show that expression of these VPS41 variants prevents
the formation of a functional HOPS complex, leading to a kinetic
defect in the delivery of endocytosed and autophagic cargo to
lysosomes. In addition, we find an inhibition of the mechanistic
target of rapamycin complex 1 (mTORC1) toward TFEB/TFE3
and concomitantly a constitutive high level of autophagy with a
failure to respond to changing nutrient conditions. Finally, we
show that compound expression of VPS41S285P and VPS41R662*
abolishes the neuroprotective effect of VPS41 in the C. elegans
model of Parkinson’s disease. To the best of our knowledge, this
is the first study on the cellular consequences of biallelic VPS41
variants in patients displaying neurological manifestations. Our
molecular analysis shows that these mutations result in an unex-
pected defect in mTORC1 signaling, specifically in the TFEB/
TFE3 axis regulating autophagy.
Patients
Clinical presentation of three patients with biallelic variants
in VPS41
Family 1 (Fig EV1A)—Patients 1 and 2, two brothers, born via spon-
taneous and vaginal delivery, at term, to healthy and non-consan-
guineous parents. Their birth weights were 3.03 kg (10th–50th
centile) and 3.34 kg (10th–50th centile), respectively. The birth
length and head circumferences were not recorded. No abnormali-
ties were noted after birth, and the babies were discharged on time.
Both presented with neonatal hypotonia and poor eye contact and
fixation at 2 months of age and both had ophthalmological exami-
nation showing hypopigmented and underdeveloped retina which
disappeared at 1 year of age. Physical examination at this stage
showed a high forehead with frontal bossing, retrognathia, deep set
eyes, short and pointed nose, and prominent ears. There was no
organomegaly. In infancy, they were noted to have global develop-
mental delay, poor muscle tone, and marked intentional tremor
which further impaired their fine and gross motor skills. Both broth-
ers developed progressive spasticity of the lower limbs with some
coarsening of the facial features more so in patient 2 with puffy
eyelids, heavy eyebrows, and thick lips. Both brothers showed
absent deep tendon reflexes (DTRs), and their plantars were exten-
sor. Both developed upper extremity tremor and significant lower
limbs’ spasticity and ataxia (Movies EV1–EV3). Extensive investiga-
tion for metabolic diseases, including lysosomal and mitochondrial
disorders, showed no detectable abnormalities. No urinary
mucopolysaccharides and oligosaccharides were detected. Cere-
brospinal fluid analysis for neurotransmitter levels showed no
abnormalities. Brain MRI done in infancy on both brothers showed
mild hypomyelination (Fig 1A and B). However, a repeat brain MRI
study on the older brother (patient 1) at 4 years 7 months showed
thin corpus callosum with a saber-shape configuration (Fig 1A) and
the vermis, although normal in configuration and size initially,
demonstrated volume loss on follow-up examinations. Furthermore,
brain MRI done on the younger brother (patient 2) at 10 years of
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age confirmed the thin corpus callosum, mild progression of the
cerebellar atrophy, bilateral hypointensity in the globus pallidus
(GP) compatible with early iron deposition, and abnormal hyperin-
tensity in the dentate nucleus (Fig 1B). The overall findings were
consistent with neurodegenerative rather than solely malformative
brain disease. The growth charts for head circumference were
within normal range (Fig EV1B).
DNA analyses using a gene panel including genes associated with
mental retardation and dystonia as well as genes associated with
iron deposition in the basal ganglia showed no detectable variants
(Appendix Table S1). Microarray analysis (IDT xGen Exome
Research Panel v1.0) revealed a de novo duplication of 2.568 Mb at
1q21.1 [GRCh37/hg19 chr1:145,804,790–148,817,029] in patient 1
only. This region partially overlaps with the 1q21.1 microduplica-
tion syndrome and is of unknown significance (Brunetti-pierri et al,
2008). Whole exome sequencing done on the brothers and their
parents showed that both patients are compound heterozygote for
variants in the VPS41 gene in trans; they carried a missense variant
in the WD40 domain [Chr7(GRCh37)[(NM_014396.3:c.853T > C,
NP_055211.2:pSer285Pro (S285P)(heterozygote, paternal); hereafter
referred to as VPS41S285P] and a nonsense variant in the Clathrin
Heavy Chain Repeat (CHCR) resulting in a truncated protein
[c.1984C > T,NP_055211.2:pArg662Stop(R662*)(heterozygote,
maternal); hereafter referred to as VPS41R662*] (Fig EV1C). The
VPS41S285P variant has mixed in silico predictors and is observed in
2/282128 (0.0007%) alleles in gnomAD. The VPS41R662* variant is
predicted to cause loss of normal protein function either through
protein truncation or nonsense-mediated mRNA decay. It is
observed in 98/282180 (0.03%) alleles in gnomAD, and no individu-
als are reported to be homozygous. The gnomAD frequencies and
predictions of pathogenicity by available software programs are
shown in Table 1.
Compound heterozygous missense variants in the ITGB4 gene
were also identified; however, ITGB4 is associated with autosomal
recessive non-Herlitz junctional epidermolysis bullosa which does
not fit the phenotype observed in this family.
A description of the whole exome sequencing technique used,
the filtering strategy, variant analysis and confirmation by Sanger
sequencing, as well as a list of rare variants detected, can be found
in the Supplements (Appendix Supplementary Methods and Dataset
EV1, respectively).
Family 2 (Fig EV1D)—Patient 3, a boy, born to a distantly
related parents of Jewish descent (common ancestor in 18th
century, Fig EV1D). The pregnancy was uneventful and delivery
was at 40wk 1d by Cesarean section for decelerations and meco-
nium-stained amniotic fluid. His birth weight was 3290 grams
(10th–50th centile). On examination, he was noted to have a head
circumference at the 3rd centile, retrognathia, short and upturned
nose, relatively large ears, clinodactyly of both 5th fingers and
hepatosplenomegaly. He was noted to be hypotonic and jittery.
He had recurrent infections during infancy and childhood, photo-
phobia, mild sensorineural hearing deficit which required hearing
aids, tracheomalacia, and a severe global delay. He developed
hypertension and a progressive spasticity of the lower limbs from
the age of 5 years onwards. His facial features coarsened over
time with heavy eyebrows, gingival hypertrophy, protruding
tongue, thick lips, and thick ear lobes (Fig EV1E I–III). He had a
pectus carinatum and short stubby hands. The liver and spleen
sizes gradually normalized, and by age 5, there was no longer
hepatosplenomegaly. At that age, the boy had severe global
developmental delay, a convergent strabismus with restricted
vertical eye movements, axial hypotonia with peripheral spastic-
ity, brisk DTRs at the upper limbs, and weak DTRs on the lower
extremities. He had short Achilles tendons with equinus feet posi-
tion. There was a dysmetry when reaching for objects, but no
tremor. In the following years, the boy developed a scoliosis and
severe spastic tetraplegia with contractures, first in the lower
extremities and later in the upper extremities (starting in the
hands). His skin felt soft and thick, and there was hirsutism on
his back and legs. He never developed the ability to sit, walk, or
speak. He was able to move in a walking device, but later lost
that ability. His ability to cough decreased from the age of
12 years, and he developed swallowing problems, resulting in
more upper airway infections. His height and head circumference
remained at 2.5 SD during the years (Fig EV1B).
Ophthalmologic investigation was normal apart from retinal
hypopigmentation. An ECG and cardiac ultrasound were normal.
Extensive metabolic investigation including analysis for peroxiso-
mal and lysosomal disorders, including urinary mucopolysaccha-
rides and oligosaccharides as well as CDG (sialo transferrines),
showed no abnormalities. A spinal X-ray showed a kyphosis at
C3 (Fig EV1F IV) and X-rays of the hands showed hypoplastic
distal phalanges on digits 2, 3, and 5 and a short metacarpal 1,
bilaterally (Fig EV1F V). A cerebral MRI showed agenesis of
the corpus callosum (Fig 1C), bilateral colpocephaly, a dysplastic
cerebellum with polymicrogyria of the upper part, and a dysplas-
tic pons.
Microarray analysis (Agilent 180 K custom HD-DGH microarray;
(AMADID-nr. 27730)) revealed no chromosomal imbalances,
targeted genetic analysis for several disease genes, and a gene panel
including approximately 800 genes associated with intellectual
disability, showed no detectable variants. Trio whole exome
sequencing showed compound heterozygous variants in the VPS41
gene; a paternal variant in the TPR-like domain [NM_014396.3:
c.1423-2A > G p.?; hereafter referred to as VPS41c.1423-2A>G] and a
maternal nonsense variant in the CHCR domain [c.1984C > T,
NP_055211.2:pArg662Stop(R662*)(heterozygote, maternal); here-
after referred to as VPS41R662*]. The c.1423-2A > G variant is a
splice site variant that destroys the canonical splice acceptor site in
intron 17 and is predicted to cause abnormal gene splicing. The
VPS41R662* nonsense variant is shared between all three patients
and heterozygously present in the healthy brother of patient 3
(Fig EV1C). Patient 3 also carried a homozygous missense variant
of unknown significance in UPF3A [NM_080687.2:c.707G > A,
NP_542418.1:pArg236Gln] for which both parents and his healthy
sibling were heterozygotes. This variant is located in an evolution-
ary conserved region, but not within a known functional domain of
the protein. At this point, variants in this gene have not been associ-
ated with any human disease.
A description of the whole exome sequencing technique used,
the filtering strategy, variant analysis, and confirmation by Sanger
sequencing, as well as a list of rare variants detected, can be
found in the Supplements (Appendix Supplementary Methods and
Dataset EV2, respectively). The gnomAD frequencies and predic-
tion of pathogenicity by available software programs are shown
in Table 1.
ª2021 The Authors EMBO Molecular Medicine 13: e13258 | 2021 3 of 24
Reini EN van der Welle et al EMBO Molecular Medicine
Results
Patient fibroblasts and VPS41KO cells contain small-sized,
acidified lysosomes active for cathepsin B
To study the cellular effects of VPS41 variants in patient cells, we
obtained skin biopsies from the youngest brother of the first family
(patient 2; VPS41S285P/R662*), patient 3 (VPS41 c.1423-2A>G/R662*), an
independent control (VPS41WT/WT), and from the father and mother
of patients 1 and 2 (VPS41WT/S285P and VPS41WT/R662*) and made
primary fibroblast cultures. In addition, we mimicked disease condi-
tions in HeLa cells using CRISPR/Cas9 methodology. We chose to
study fibroblasts from patient 2, because patient 1 also displayed the
de novo duplication at Chr1q21.1, which partially overlaps with the
1q21.1 microduplication syndrome (Brunetti-pierri et al, 2008). The
clinical features of patient 1 are more severe than in individuals suf-
fering from 1q21.1 duplication syndrome; however, we cannot rule
out that patient fibroblasts are affected by this duplication. Similarly,
patient 3 bears a homozygous mutation in UPF3A of unknown
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First, we studied the effects of the VPS41 mutations on lysosomal
morphology in the VPS41S285P/R662* fibroblasts. Electron microscopy
(EM) showed a high variation in appearance of endolysosomal
compartments (Fig EV2A–D), but no inclusion bodies. This indi-
cates that mutations in VPS41 do not cause a classical lysosomal
storage phenotype (Papa et al, 2010), which is in agreement with
the metabolic studies performed on patient fibroblasts, leucocytes,
and urine (see patient descriptions). To study lysosomal acidifi-
cation and hydrolase activity, we performed fluorescence micro-
scopy using MagicRed cathepsin B. This showed an increase in the
number of cathepsin B-active puncta as compared to control or
parental cells (Appendix Fig S1A, quantified in S1A’). Concomi-
tantly, immunofluorescence of the lysosomal membrane protein
LAMP-1 showed a significant increase in both patients (Fig 2A,
quantified in 2A’). Similarly, HeLaVPS41KO cells, i.e., HeLa cells
knockout for VPS41 using CRISPR/Cas9 methodology (Fig 2B),
showed numerous small LAMP-1 puncta (Fig 2C, quantified in 2C’)
and an increase in acidic compartments, investigated using Lyso-
tracker-Green (Appendix Fig S1B, quantified in S1B’).
LAMP-1 resides in lysosomes as well as late endosomes, which
by EM can be distinguished by the presence or absence of degraded
material, respectively (Peden et al, 2004; Huotari & Helenius, 2011;
Pols et al, 2013a; Klumperman & Raposo, 2014). By immuno-EM,
we found that VPS41S285P/R662* fibroblasts contain LAMP-1-positive
late endosomes and lysosomes (Fig 2D), which were also positively
labeled for cathepsin B (Appendix Fig S1C). However, in agreement
with the fluorescent microscopy observations, morphologically
identified, LAMP-1-positive lysosomes in patient-derived cells were
significantly smaller than in VPS41WT/WT, VPS41WT/S285P or
VPS41WT/R662* fibroblasts (Fig 2E). The relative labeling density (an
indication for protein concentration per membrane unit) of LAMP-1
in lysosomes remained equivalent to control cells (Fig 2F), but since
lysosomes were smaller, the total number of gold particles (indica-
tion for total amount of LAMP-1) had decreased (Fig 2G). Similar
data were obtained for LAMP-2 (Appendix Fig S2A and B).
These data show that lysosomes in patient cells contain LAMP-1,
LAMP-2, and cathepsin B, but are considerably smaller in size than
in control cells. We conclude that biallelic expression of VPS41R662*
with VPS41S285P or VPS41c.1423-2A>G, as well as the absence of VPS41
by gene knockout, induces an increase in small-sized, enzymatically
active lysosomes, which at steady state conditions contain normal
LAMP levels.
VPS41R662* is not detectable in fibroblasts
To establish expression levels of the VPS41 variants, we performed
quantitative Western blots of patients and parental fibroblasts.
Wild-type VPS41 was readily detectable in VPS41WT/R662* fibroblasts
◀ Figure 1. Mutations in VPS41 cause a neurodegenerative disease.
A Patient 1 (older sibling) underwent 3 MRI studies, first and last are shown. Top row: 21 months; Bottom row: 4 years 7 months. The corpus callosum is thin on T1-
weighted sagittal images (I, V, VI) with a saber shape (long arrows). The shape remains consistent over time. The vermis is normal in configuration and size initially (I),
but demonstrates volume loss on follow-up (V, VI) examination (short arrows). FLAIR axial image (II) is age appropriate, while (VII) demonstrates periatrial increased
signal (arrow). There is delay in myelin maturation present on T1 (III, VIII)- and T2 (IV, IX)-weighted axial images (long arrows) on initial examination, with further
slow myelin development over time. There is deficiency of periatrial white matter volume on both T1 (III, VIII)- and T2 (IV, IX)-weighted axial images (short arrows).
Coronal T2 image (V) demonstrates abnormally increased signal of the dentate nuclei (arrow), unchanged on follow-up image (X). Superior vermian atrophy (short
arrows) over time.
B Patient 2 (younger sibling). Top row: 4 years, 11 months; Bottom row: 9 years, 6 months. The corpus callosum is thin with a saber-shape (long arrows) configuration
on T1-weighted sagittal (I) and T2-weighted sagittal (V, VI). The shape remains consistent over time, although the volume decreases slightly. The vermis demonstrates
volume loss on both sagittal examinations (short arrows). There is iron deposition in the basal ganglia on FLAIR (VII) and T2-weighted coronal (VIII) and axial (IX)
images at 9 years 8 months of age (arrow). This was not present on earlier imaging. Iron deposition was also present in the subthalamic nuclei (not shown). Myelin
maturation is age appropriate on the initial T1-weighted axial image (III) and minimally delayed on T2-weighted image (IV) at 4 years 11 months of age (short
arrow). Myelin is age appropriate (short arrow) on follow-up T2-weighted images (VIII, IX). The dentate nuclei (short arrows) are bright on T2 coronal images (V, VI, X)
at both ages. There is progressive cerebellar hemisphere volume loss.
C Patient 3, 3 weeks old. Sagittal T1-weighted image (I) demonstrates a very thin severely hypoplastic remnant of corpus callosum (short arrow), a short cingulate
sulcus (long arrow), and slender pons. FLAIR image (II) reveals faintly increased signal (short arrow) in the posterior limb of internal capsule (PLIC). There is lack of
myelin maturation in the PLIC (short arrows) on T1-IR (III)- and T2 (IV)-weighted axial images. Focal widening of the interhemispheric CSF space (arrow) on T2-
weighted image (IV) reflects the absence of rostral fiber tracts. Cingulate gyrus is present (long arrow). No traversing callosal fibers are shown at this level (I).
Table 1. Prediction of pathogenicity of VPS41 variants.
VPS41 (NM_014396.3) gnomAD global SIFT CADD PolyPhen2 HDIV PolyPhen2 HVAR Patient









c.1984 C > T p.R662* 0.00035; 98/282180 (b) 40 (b) (b) 1, 2 and 3
c.1423-2A > G p.? (a) 0.000032; 1/31398 (b) 34 (b) (b) 3
Frequency of the specific VPS41 variants in the general population based on the gnomAD database ([variants observed]/[total of individuals studied]) (http://
gnomad.broadinstitute.org/) and prediction of pathogenicity based on the programs SIFT, (https://sift.bii.a-star.edu.sg/), CADD (https://cadd.gs.washington.edu/),
and PolyPhen (http://genetics.bwh.harvard.edu/pph2/).
(a): Three different splice site analysis programs (MaxEnt, NNSPLICE, and SSF) predict a total loss of wild-type acceptor splice site (Interactive Biosoftware -
Created by Alamut Visual v.2.15.0).
(b): Not determined; SIFT and PolyPhen2 programs can only be used for analysis of missense mutations.
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from the mother of patients 1 and 2 (Fig 3A). Also in the pater-
nal VPS41WT/S285P fibroblasts there was a strong signal for full-
length VPS41, in this case representing both VPS41WT and
VPS41S285P (Fig 3A). VPS41R662*, the variant shared between all 3
patients, encodes for a premature stop codon predicted to result
in a truncated protein of lower molecular weight. However, we
could not detect a lower VPS41R662* band in either VPS41S285P/R662*
patient or VPS41WT/R662* maternal fibroblasts (Fig 3A,
Appendix Fig S3A). Treatment with proteasome inhibitor MG132,
to prevent degradation of VPS41R662*, did not change this
outcome. Since the VPS41R662* variant is recognized by the
VPS41 antibody, these data indicate that VPS41R662* protein levels
in fibroblasts are below detection. RNA bearing a premature stop
codon can be prematurely degraded via Nonsense-Mediated Decay
(NMD). To determine whether this is the case for VPS41R662*, we
performed RT–PCR on VPS41WT/WT, VPS41WT/R662*, VPS41WT/S285P,
and VPS41S285P/R662* fibroblasts. Indeed, maternal and patient
fibroblasts showed a significant decrease in VPS41 mRNA levels
(Appendix Fig S3B). Together, these data show that VPS41R662*
mRNA levels are below detection due to premature degradation
of the mutant mRNA. In contrast to VPS41R662*, the VPS41S285P
variant was readily detectable in Western blots of VPS41S285P/R662*
fibroblasts (Fig 3A). Since this is the only allele that is expressed,
the total VPS41 expression was lower than in control cells
(Fig 3A’). Finally, our Western blot analysis revealed a striking
reduction, to circa 10% of wild-type levels, of VPS41 protein
levels in VPS41c.1423-2A>G/R662* fibroblasts (Fig 3A, quantified in
3A’ and Appendix Fig S3A). Since the VPS41R662* variant is not
expressed, these data indicate that the VPS41c.1423-2A>G variant is
expressed at a very low level.
We conclude from these data that fibroblasts of patients 1 and 2
only contain substantial levels of VPS41S285P, whereas cells of
patient 3 only contain circa 10% of the VPS41c.1423-2A>G variant.
VPS41S285P interacts with other HOPS subunits, Arl8b and Rab7
In control conditions, VPS41 interacts with other HOPS subunits
and the small GTPases Rab7 and Arl8b (Lin et al, 2014; Khatter
et al, 2015). To study whether VPS41 mutations affect HOPS assem-
bly, we performed co-immunoprecipitation (co-IP) studies. We
focused on VPS41S285P, being the only variant significantly
expressed in patient cells (Fig 3A), and included VPS41R662* as
negative control, since VPS41–HOPS interaction requires the pres-
ence of the C-terminal RING domain absent in VPS41R662*
(Fig EV1C; Hunter et al, 2017). We performed the co-IP studies in
HeLa cells expressing GFP-tagged constructs of VPS41WT,
VPS41S285P, or VPS41R662* and, respectively, FLAG- and HA-tagged
constructs of the HOPS core components VPS18 or VPS33A. As
expected, the truncated VPS41R662* mutant clearly showed reduced
interactions with the other HOPS subunits (Fig 3B and Appendix Fig
S4A). By contrast, the point mutation VPS41S285P did not affect
interaction with VPS18 and VPS33A (Fig 3B and Appendix Fig S4A).
Additionally, we examined in HeLaVPS41KO cells the interaction
between endogenous VPS18 and GFP-tagged VPS41 constructs. We
found that GFP-VPS41S285P and GFP-VPS41WT bind endogenous
VPS18 with similar affinities, whereas no interaction between
endogenous VPS18 and VPS41R662* was found (Appendix Fig S4B).
These data indicate that VPS41S285P can correctly bind to the HOPS
complex, whereas VPS41R662* lacks this ability. Hence, if VPS41R662*
would be expressed at sufficient levels, it would not be incorporated
in the HOPS complex.
Next, we performed co-IPs using transiently transfected HeLaWT
cells with APEX-V5-tagged VPS41 constructs and FLAG and GFP-
tagged constructs of Rab7 and Arl8b, respectively. This showed
that both VPS41S285P and VPS41R662* bind Rab7 and Arl8b to the
same extent as VPS41WT (Fig 3C). The subcellular distribution of
the distinct VPS41 constructs was explored by immunofluores-
cence microscopy. VPS41WT was present in the cytoplasm as well
as in distinct fluorescent puncta that colocalized with LAMP-1,
consistent with previous studies (Khatter et al, 2015; Jia et al,
2017; Fig 3D). Remarkably, both VPS41S285P and VPS41R662*
showed a similar distribution as VPS41WT, despite the lack of the
C terminus in VPS41R662*. Since VPS41R662* binds Rab7 and Arl8b
(Fig 3C), these interactions could mediate recruitment of
VPS41R662* to late endosomes and lysosomes independent of its
C-terminus or the HOPS complex.
◀ Figure 2. VPS41 patient and HeLa VPS41 knockout cells contain more but smaller lysosomes.
A Immunofluorescence microscopy of control, parental, and patient fibroblasts labeled for LAMP-1. Patient fibroblasts (VPS41S285P/R662* and VPS41c.1423-2A>G/R662*) show
more LAMP-1 puncta, which are distributed throughout the cell. (A’) Quantification shows a significant increase in the number of LAMP-1-positive compartments for
both patients. > 15 Cells per condition were quantified (n = 3). Scale bars, 10 µm.
B HeLa VPS41 knockout (HeLaVPS41KO) cells made using CRISPR/Cas9 methodology. Western blot analysis confirms a full knockout. The same HeLaWT and HeLaVPS41KO
samples were analyzed in Appendix Fig S8C, showing the same actin control.
C LAMP-1 immunofluorescence of HeLaWT and HeLaVPS41KO cells. Similar to patient-derived fibroblasts, more LAMP-1-positive compartments are seen in HeLaVPS41KO
cells (quantified in C’). > 10 Cells per cell line per experiment were quantified (n = 3). Scale bars, 10 µm.
D Immuno-electron microscopy of VPS41WT/WT and VPS41S285P/R662* fibroblasts incubated for 2 h with BSA conjugated to 5 nm gold (BSA-Au5) and labeled for LAMP-1
(10 nm gold particles). Lysosomes are recognized by the presence of degraded, electron-dense material. LE = late endosome, LY = lysosome, PM = plasma
membrane. Scale bar, 200 nm.
E Morphometrical analysis showing that lysosomes in patient fibroblasts are significantly smaller than in control and parental cells. > 100 Randomly selected
lysosomes per condition were quantified.
F Relative labeling density of LAMP-1. Number of LAMP-1 gold particles per lysosome was divided by the number of grid intersections, representing lysosomal size. No
significant difference was found between VPS41WT/WT, VPS41WT/S285P, VPS41WT/R662* or VPS41S285P/R662* fibroblasts. > 53 Lysosomes per condition were quantified.
G Quantitation of LAMP-1 gold particles per lysosome. VPS41S285P/R662* lysosomes have significantly less LAMP-1 then control and parental cells. > 53 Lysosomes per
condition were quantified. Similar results were obtained for LAMP-2 (Appendix Fig S2).
Data information: Data are represented as mean  SEM. *P < 0.05, **P < 0.01, ****P < 105. One-way ANOVA with Tukey’s correction (A’, E, F and G) or Unpaired t-test
(C’). Exact P-values are reported in Appendix Table S3.
Source data are available online for this figure.
ª2021 The Authors EMBO Molecular Medicine 13: e13258 | 2021 7 of 24

























































































































































































































































































































































































































































8 of 24 EMBO Molecular Medicine 13: e13258 | 2021 ª2021 The Authors
EMBO Molecular Medicine Reini EN van der Welle et al
Summarizing, these co-IP experiments show that VPS41S285P has
retained the capacity to bind the HOPS components VPS18 and
VPS33A, as well as Rab7 and Arl8b. VPS41R662* does not bind other
HOPS components, but still interacts with Rab7 and Arl8b. Both
VPS41S285P and VPS41R662* are distributed between the cytoplasm
and LAMP-1-positive endo-lysosomes.
VPS41S285P causes a defect in HOPS-dependent late
endosome–lysosome fusion
Depletion of VPS41 by RNAi results in a decrease in HOPS-depen-
dent fusion between late endosomes and lysosomes (Swetha et al,
2011; Pols et al, 2013a). To establish the effect of VPS41S285P on
HOPS functionality, we transiently transfected HeLaVPS41KO cells
with APEX2-V5 tagged constructs of VPS41WT, VPS41S285P, or
VPS41R662*. Cells were incubated for 2 h with the endocytic marker
Dextran-Alexa Fluor 568 (Dextran-568) combined with SiR-Lyso-
some to mark active cathepsin D compartments. Colocalization
between these probes indicates the transfer of endocytosed cargo to
enzymatically active lysosomes, which is HOPS dependent. VPS41KO
cells transfected with Empty Vector (EV) showed low levels of colo-
calization (Fig 3E and Appendix Fig S5A), which was increased by
transfection with VPS41WT, indicating a restoration of HOPS func-
tion (Fig 3E and Appendix Fig S5A). As expected, transfection with
VPS41R662* did not rescue the endocytosis defect, since VPS41R662*
fails to bind other HOPS components (Fig 3B and Appendix Fig S4).
Surprisingly, however, VPS41S285P also failed to rescue the endocy-
tosis defect (Fig 3E and Appendix Fig S5A). Thus, even though
VPS41S285P binds VPS18 and VPS33A (Fig 3B and Appendix Fig S4)
and localizes to endo-lysosomes (Fig 3D), it does not form a func-
tional HOPS complex. A plausible explanation for this defect is
misfolding of the VPS41S285P protein due to the Arginine to
Proline substitution.
These data show that, despite its ability to bind other HOPS
components, VPS41S285P cannot form a functional HOPS complex.
Patient fibroblasts are compromised in delivery of endocytosed
cargo to enzymatically active lysosomes
The data so far indicate that all patient-derived VPS41 variants
prevent formation of a functional HOPS complex. To assess the
process of late endosome–lysosome fusion in patient cells, we
performed the Dextran-568 and SiR-Lysosome cathepsin D colo-
calization assay in primary fibroblasts of patient 2 and his
parents. A similar assay with VPS41c.1423-2A>G/R662 cells of patient
3 failed to be successful, since these cells are very vulnerable
and died upon incubation with SiR-Lysosome. We found a signif-
icant endocytosis defect in VPS41S285P/R662* patient fibroblasts
(Fig 3F and Appendix Fig S5B) and, unexpectedly, also in the
maternal VPS41WT/R662* cells. By contrast, VPS41WT/S285P (pater-
nal) fibroblasts were not affected in endocytosis (Fig 3F and
Appendix Fig S4B).
To pinpoint the block in endocytosis at the EM level, we incu-
bated primary fibroblasts for 2 h with the endocytic marker BSA
conjugated to 5 nm gold particles (BSA-Au5) and processed cells for
immuno-EM. Sections were labeled for LAMP-1 or LAMP-2 and
randomly screened for LAMP-positive lysosomes (Klumperman &
Raposo, 2014) that were scored positive or negative for BSA-Au5
◀ Figure 3. VPS41 variants delay HOPS-dependent late endosome–lysosome fusion.
A Western blot of primary fibroblasts derived from patient 2 (VPS41S285P/R662*), his mother (VPS41WT/R662*), father (VPS41WT/S285P), patient 3 (VPS41c.1423-2A>G/R662*) and an
unrelated, healthy control (VPS41WT/WT) (Western blot of longer exposure time shown in Appendix Fig S3A). Full-length VPS41 (FL VPS41), representing VPS41WT and
VPS41S285P, is observed in all cells. Truncated VPS41R662* in patients and maternal fibroblasts is not detectable. VPS41R662* is also not visible in fibroblasts treated with
50 µM MG132 (4 h) to inhibit proteasomal degradation, indicating that the mRNA encoding for this mutant is degraded. (A’) Quantification of VPS41 protein levels
show a reduction in both patients compared with VPS41WT/WT, with only 10% remaining VPS41 levels in VPS41c.1423-2A>G/R662* (n = 2).
B Immunoprecipitation (IP) on HeLa cells co-expressing GFP-empty vector (EV), GFP-VPS41WT, GFP-VPS41S285P, or GFP-VPS41R662* and FLAG-VPS18. GFP-VPS41WT and
GFP-VPS41S285P both interact with FLAG-VPS18 and as shown in Appendix Fig S4A with HA-VPS33A. Interaction between GFP-VPS41R662* and FLAG-VPS18 is strongly
reduced. Note that the stop codon in VPS41R662* leads to a truncated protein of lower molecular weight (n = 3).
C IP on Hela cells co-expressing VPS41WT-APEX2-V5, VPS41S285P-APEX2-V5, or VPS41R662*-APEX2-V5 and FLAG-RAB7 or GFP-Arl8b. The IP was performed on FLAG or GFP,
respectively. All VPS41 variants interact with Rab7 and Arl8b (n = 3).
D HeLaVPS41KO cells transfected with VPS41WT-APEX2-V5, VPS41S285P-APEX2-V5, or VPS41R662*-APEX2-V5 constructs labeled for LAMP-1 and V5 immunofluorescence
microscopy. All VPS41 variants colocalize with LAMP-1, indicating that VPS41S285P and VPS41R662* are recruited to late endosomes/lysosomes. Scale bars 10 µm; zoom
of squared area, 1 µm.
E Quantification of endocytosis-rescue experiments in HeLa cells. HeLaVPS41KO cells transfected with VPS41WT-APEX2-V5 show a significant increase in colocalization of
endocytosed Dextran-568 and SiR-Lysosome cathepsin D (SiR-Lyso), indicating rescue of the endocytosis phenotype. Neither VPS41 variant rescues this HOPS complex
functionality. >13 Cells per cell line per experiment were quantified (n = 3).
F Quantification of lysosomal delivery of endocytosed cargo in fibroblasts, based on fluorescent data. VPS41WT/WT, VPS41WT/S285P, VPS41WT/R662*, and VPS41S285P/R662*
primary fibroblasts were incubated with Dextran-568 and SiR-Lysosome cathepsin D (SiR-Lyso) for 2 and 3 h, respectively. Colocalization representing delivery of
Dextran to enzymatically active lysosomes is reduced in VPS41WT/R662* and VPS41S285P/R662* cells. >11 Cells per cell line per experiment were quantified (n = 3).
G Quantification of lysosomal delivery of endocytosed cargo in fibroblasts, based on EM data. VPS41WT/WT, VPS41WT/S285P, VPS41WT/R662*, and VPS41S285P/R662* fibroblasts
were incubated with BSA-Au5 for 2 h and labeled for LAMP-1 (10 nm gold particles) immuno-EM (Fig 2D). LAMP-1-positive lysosomes were scored for presence of
BSA-Au5, and the ratio between BSA+ and BSA- lysosomes was calculated. >46 Lysosomes per condition were quantified. Both VPS41WT/R662* and VPS41S285P/R662* show
a strong decrease in BSA-positive lysosomes indicating a fusion defect between late endosomes and lysosomes.
H VPS41WT/WT, VPS41WT/R662*, and VPS41S285P/R662* primary fibroblasts incubated with Dextran-568 for 0.5, 2, 5, 8, and 24 h. Colocalization of Dextran-568 and SiR-
Lysosome cathepsin D (SiR-Lyso) reveals a delay in lysosomal delivery in maternal (VPS41WT/R662*) and patient (VPS41S285P/R662*) cells at 2 h of Dextran uptake. After
5 h, maternal cells show similar to control colocalization levels. Patient cells show only after 24 h colocalization levels similar to control, indicating a delay rather
than a block in late endosome–lysosome fusion. > 10 Cells per cell line were quantified.
Data information: Data are represented as mean  SEM. *P < 0.05, ***P < 104. Unpaired t-test (A’), one-way ANOVA with Bonferroni correction (E) or one-way ANOVA
with Tukey’s correction (F). Exact P-values are reported in Appendix Table S3.
Source data are available online for this figure.
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(Fig 2D). In agreement with the data from florescence microscopy,
this showed a decrease in the delivery of BSA-Au5 to LAMP-positive
lysosomes in VPS41S285P/R662* patient and VPS41WT/R662* maternal
fibroblasts (Fig 3G). The paternal VPS41WT/S285P fibroblasts were not
affected. Collectively, these fluorescent and EM data indicate that
transfer of endocytosed cargo to enzymatically active, LAMP-positive
lysosomes is affected in fibroblasts of patient 2 and of his mother.
Since the mother of the patients does not show a clinical pheno-
type, we reasoned that the defect in lysosomal delivery could be
kinetic rather than a complete block. To test this, we incubated
control, maternal, and patient fibroblasts with Dextran-568 for
several time points, after which we determined colocalization with
SiR-Lysosome (Fig 3H). After 2 h, VPS41WT/R662* as well as
VPS41S285P/R662* fibroblasts again displayed significant lower levels
of colocalization than VPS41WT/WT cells. After 5 h, however, the dif-
ference between maternal and control fibroblasts was abolished,
whereas patient fibroblasts still showed a significant lower level of
Dextran in lysosomes. After 24 h of Dextran-568 uptake, patient
fibroblasts showed a similar level of colocalization with SiR-Lyso-
some as control and maternal cells (Fig 3H).
Together, these data show that expression of VPS41S285P or
absence of VPS41 causes a deficiency in transfer of endocytic cargo
to lysosomes, representing a defect in HOPS-dependent endolysoso-
mal fusion. This defect is a delay rather than a block in fusion,
which in patient cells is more severe than in maternal fibroblasts,
indicating that transport kinetics is an important determinator of
pathogenesis. The data also show that in maternal fibroblasts the
consequence of carrying the VPS41R662* variant is not fully compen-
sated for by the VPS41WT allele, yet this does not result in a patho-
genic phenotype.
Patient fibroblasts have a defect in autophagic response
to starvation
In addition to late endosome–lysosome fusion, the HOPS complex is
required for fusion of autophagosomes with lysosomes (Jiang et al,
2014; McEwan et al, 2015; Nakamura & Yoshimori, 2017). A block in
autophagosome-lysosome fusion results in increased numbers of
autophagosomes containing lipidated LC3 (LC3II) and hence an
increase in LC3II:LC3I ratio. We quantified this on Western blot and
found that under nutrient-rich conditions, the LC3II:LC3I ratio is
increased in VPS41S285P/R662* (patient 2) fibroblasts compared with
control cells, indicating that patient cells have more autophagosomes
(Fig 4A, quantified in 4A’). To verify these findings, we performed
immunofluorescent labeling of LC3 in patient and control fibroblasts.
This confirmed that VPS41S285P/R662* cells contain significantly more
LC3-positive compartments than VPS41WT/WT cells (Fig 4B, quanti-
fied in 4B’). Starvation induced an increase in numbers of
autophagosomes in both control and patient fibroblasts (Fig 4B,
quantified in 4B’). Intriguingly, however, whereas in control fibrob-
lasts this increase was 13.4-fold, in patient fibroblasts only a 3.8-fold
increase was attained. These data indicate that VPS41 patient fibrob-
lasts sustain a higher basal level of autophagy and are less respon-
sive to nutrient starvation than control fibroblasts.
We further studied this phenomenon in HeLaVPS41KO cells. Under
nutrient-rich conditions, LC3II levels in HeLaVPS41KO cells were
significantly elevated compared to HeLaWT cells (Fig 4C, quantified
in 4C’). A similar upregulation was seen in a previous study in
VPS41-depleted HeLa cells (Ding et al, 2019). Concomitantly,
immunofluorescence of HeLaVPS41KO cells revealed an increase in
LC3 puncta (Fig 4D, quantified in 4D’). Strikingly, starvation of
HeLaVPS41KO cells did not further increase LC3II protein levels or
number of LC3 puncta (Fig 4C and D). Rescue of HeLaVPS41KO cells
with VPS41WT reduced the number of LC3 puncta and restored the
capacity of cells to respond to starvation and restimulation (Fig 4D,
quantified in 4D’). By contrast, expression of VPS41S285P or
VPS41R662* did not restore the autophagic flux (Fig 4D, quantified in
4D’). Together, these data show that both patient fibroblasts and
VPS41KO cells have increased basal autophagy levels. Patient fibrob-
lasts respond to starvation, but not to a similar extent as control
fibroblasts. On the contrary, HeLaVPS41KO cells are impaired in their
responsiveness to starvation.
To follow the autophagic flux from autophagosome to lyso-
some, we next transfected HeLaWT and HeLaVPS41KO cells with an
LC3GFP/RFP tandem construct. GFP and RFP co-label autophago-
somes, whereas the GFP signal is quenched in the acidic environ-
ment after autophagosome–lysosome fusion (Kimura et al, 2007).
Immunofluorescence of HeLaVPS41KO cells showed a significant
higher level of GFP/RFP colocalization than HeLaWT cells, indicat-
ing that in the absence of VPS41, autophagosome–lysosome fusion
is impaired (Fig 4E, quantified in 4E’). To confirm these findings,
we incubated HeLaWT and HeLaVPS41KO cells with Bafilomycin A1
(BafA1), which increases the lysosomal pH and prevents degrada-
tion of LC3. Indeed, Western blots of BafA1-treated WT cells
showed an increase in LC3II protein levels, however, not to a simi-
lar level as non-treated, non-starved VPS41KO cells (Fig EV3A,
quantified in EV3B and C). Strikingly, starvation of WT cells in the
presence of Baf1A resulted in similar LC3II levels as starved
VPS41KO cells in the absence of Baf1A (Fig EV3C). Overall, BafA1
treatment of VPS41KO cells had little effect on LC3II protein levels
(Fig EV3A, quantified in EV3B). These data indicate that LC3II in
VPS41KO cells is less well degraded by lysosomes than in control
cells, consistent with the HOPS-dependent role of VPS41 in
autophagosome–lysosome fusion.
Together, the data indicate that VPS41S285P/R662* fibroblasts have
increased basal autophagic levels and are, to some extent, respon-
sive to autophagic stimuli. VPS41KO cells also have high basal
autophagy levels, but are virtually insensitive to starvation. The dif-
ferences between patient fibroblasts and HeLaVPS41KO cells could be
due to differences in autophagic responsiveness in these cell types.
Alternatively, the patient cells might have developed epigenetic
compensatory mechanisms.
VPS41 deficiency causes a HOPS-dependent defect on the TFE3
but not S6K1/4EBP1 axis
A complex of v-ATPase/Ragulator/Rag GTPases present at the lyso-
somal membrane senses nutrient status in lysosomes and, in nutri-
ent-rich conditions, recruits the mTORC1 complex. Upon nutrient
deprivation, mTORC1 dissociates from the lysosomal membrane
and loses its kinase activity toward p70 ribosomal protein S6 kinase
1 (S6K1), 4E-binding protein 1 (4EBP1), and the transcription
factors TFEB and TFE3. Consequently, TFEB and TFE3 translocate
to the nucleus where they activate the CLEAR (Coordinated Lysoso-
mal Expression and Regulation) network that induces lysosomal
biogenesis and autophagy (Palmieri et al, 2011). LC3 is a target of
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the CLEAR network, and mTORC1 inhibition results in enhanced
LC3 levels (Palmieri et al, 2011). Since patient-derived fibroblasts
and VPS41KO cells show increased LC3 levels under basal conditions
(Fig 4A–D), we investigated mTORC1 and TFE3 localization and
activity in VPS41 patient fibroblasts and VPS41KO cells.
We first studied recruitment of mTORC1 to lysosomes by
immunofluorescence microscopy, monitoring colocalization with
LAMP-1. As expected, we found significant overlap between
mTORC1 and LAMP-1 puncta in control VPS41WT/WT fibroblasts
grown in nutrient-rich conditions. After 2-h starvation, mTORC1
had redistributed to the cytoplasm, and after 15-min restimulation,
the colocalization with LAMP-1-positive lysosomes was partially
restored (Fig 5A). The parental derived fibroblasts VPS41WT/S285P
and VPS41WT/R662* followed this same pattern (Appendix Fig S6).
However, in patient-derived VPS41S285P/R662* fibroblasts, mTORC1–
LAMP-1 colocalization was strikingly less in all conditions and did
not change upon starvation or restimulation. Quantitation of
mTORC1/LAMP-1 colocalization, for each cell type relative to the
control condition (0 h), clearly showed that VPS41S285P/R662 fibrob-
lasts do not alter mTORC1 localization in response to starvation
(Fig 5A, quantified in 5A’). To monitor the effect of mTORC1 disso-
ciation on TFEB/TFE3 localization, we labeled fibroblasts for
endogenous TFE3 (Fig 5B). In VPS41WT/WT, VPS41WT/S285P, and
VPS41WT/R662* fibroblasts, TFE3 showed a normal localization
pattern, and translocated to the nucleus in response to starvation
(Fig 5B, quantified in 5B’). However, in VPS41S285P/R662* fibroblasts,
TFE3 was constitutively found in the nucleus, regardless of nutrient
conditions. A similar constitutive nuclear localization of TFE3 was
observed in fibroblasts obtained from patient 3 (VPS41c.1423-2A>G/R662*,
Fig EV4A). These data show that TFE3 is continuously present in
the nucleus of patient cells, regardless of nutrient status.
We then performed similar experiments in HeLa VPS41KO cells.
Like patient fibroblasts, these cells showed impaired lysosomal
recruitment of mTORC1 (Fig EV4B). Reintroducing VPS41WT into
HeLaVPS41KO cells increased the colocalization of mTORC1 with the
lysosomal marker cathepsin D from 15 to 30%. Expression of
VPS41S285P or VPS41R662* slightly increased lysosomal recruitment
of mTORC1, but to a much lesser extent than VPS41WT (Fig EV4C
and D). Concomitantly, HeLaVPS41KO cells showed the “TFE3 translo-
cation to the nucleus phenotype” (Fig 5C, quantified in 5C’), and the
same was observed in PC12VPS41KO cells (Fig EV4E, Appendix Fig
S7A and B). Expression of VPS41WT in HeLaVPS41KO cells rescued the
TFE3 phenotype after starvation and restimulation, whereas expres-
sion of VPS41S285P or VPS41R662* had no effect; TFE3 was present in
the nucleus in all conditions (Fig 5D, quantified in 5D’). Notably,
transfection of cells affects membrane integrity causing lysosomal
stress. This likely explains the nuclear localization of TFE3 in
HeLaVPS41KO cells transfected with VPS41WT when cultured under
steady state conditions (Fig 5D). Similar to TFE3, TFEB is also phos-
phorylated by mTORC1 to prevent nuclear translocation. Phosphory-
lation induces a molecular weight shift visible on Western blot. To
address whether TFEB phosphorylation is affected in VPS41KO cells,
we analyzed this in control conditions and upon starvation. We used
the mTORC1 inhibitor Torin-1 as positive control to show the molec-
ular weight shift of TFEB. Indeed, starvation of HeLaWT cells resulted
in a similar molecular weight shift as observed after Torin-1 treat-
ment (Fig EV4F). By contrast, HeLaVPS41KO cells did not respond to
starvation or Torin-1 treatment, indicating that TFEB phosphoryla-
tion is impaired (Fig EV4F). The continuous nuclear localization of
TFE3 in patient cells predicts an increase in expression of lysosomal
and autophagy proteins (Settembre et al, 2011; Martina et al, 2014).
Western blot analysis indeed showed that protein levels of LAMP-1
and the lysosomal hydrolase cathepsin B, both CLEAR targets, are
increased in patient fibroblasts (Appendix Fig S8A and B). Similar
results were obtained for LAMP-1 and cathepsin D in VPS41KO cells
(Appendix Fig S8C). Collectively, these data show that in cells lack-
ing VPS41 or expressing VPS41S285P and/or VPS41R662*, regulation of
the mTORC1/TFE3 axis is perturbed, resulting in higher levels
of autophagy and lysosome proteins and a continuous activation of
autophagy, independent of nutrient status.
A possible explanation for the mTORC1/TFE3 phenotype is that
the defect in HOPS function results in insufficient delivery of nutri-
ents to lysosomes and subsequent mTORC1 dissociation. If so, any
block in HOPS function should give this phenotype. To test this, we
made HeLaKO cells for VPS11, VPS18, and VPS39, which are part of
HOPS but not required for the ALP/LAMP pathway (Pols et al,
▸Figure 4. Patient fibroblasts and VPS41KO cells show decreased autophagic flux and response to autophagic stimuli.A Western blot of LC3 expression levels in control and patient fibroblasts. In steady state conditions (0 h), patient fibroblasts have a higher ratio of lipidated LC3 (LC3II):
LC3I than control cells. Induction of autophagy by nutrient starvation (2 h incubation with minimal EBSS medium) results in a raise in LC3II:LC3I ratio in both control
and patient cells, but in VPS41S285P/R662* fibroblasts this increase is only modest (quantified in A’) (n = 2).
B Immunofluorescence of LC3 inVPS41WT/WT and VPS41S285P/R662* fibroblasts under steady state and starved conditions. At steady state conditions (0 h), patient
fibroblasts contain more LC3-positive compartments. Nutrient starvation (2 h) increases the number of LC3-positive autophagosomes in control fibroblasts 13.4-fold,
and in VPS41S285P/R662* fibroblasts only 3.8-fold, indicating a reduced responsiveness to starvation (quantified in B’). > 54 Cells per cell line were quantified. Scale bars,
10 µm.
C Western blot analysis of HeLaVPS41KO cells shows a fourfold increase in LC3II protein levels in steady state conditions (0 h) compared with HeLaWT cells. In contrast to
control cells, nutrient starvation (2 h) did not increase LC3II protein levels in HeLaVPS41KO cells, indicating irresponsiveness to nutrient availability (quantified in C’)
(n = 3).
D Rescue experiments. HeLaVPS41KO cells transfected with EV-APEX2-V5, VPS41WT-APEX2-V5, VPS41S285P-APEX2-V5, or VPS41R662*-APEX2-V5 and labeled for V5 and LC3 by
immunofluorescence microscopy. Rescue with VPS41WT-APEX2-V5 decreases the number of LC3-positive compartments in steady state conditions (0 h) and restores
responsiveness to nutrient starvation (2 h) and replenishment (2-hour starvation followed by 15 min restimulation). Neither of the mutant VPS41 variants rescues
this autophagy phenotype (quantified in D’). >15 Cells per condition were quantified (n = 3). Scale bars, 10 µm.
E Immunofluorescence of HeLaWT and HeLaVPS41KO cells transfected with LC3GFP/RFP tandem construct. The increased percentage of GFP/RFP-positive compartments in
HeLaVPS41KO cells indicates a block in autophagic flux (quantified in E’). > 12 Cells per cell line were quantified. Scale bars 10 µm; zoom, 1 µm.
Data information: Data are represented as mean  SEM. *P < 0.05, **P < 0.01, ***P < 104, ****P < 105. Unpaired t-test (A’ and E’) or one-way ANOVA with Tukey’s (B’)
or Bonferroni correction (C’ and D’). Exact p-values are reported in Appendix Table S3.
Source data are available online for this figure.
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2013b; Appendix Fig S9A and B). Similar to VPS41KO cells, an
increase in endolysosomal compartments was observed by
immunofluorescent labeling of cathepsin D (Fig EV5A, quantified in
EV5A’). VPS11KO and VPS18KO cell lines showed increased LC3II
protein levels in basal conditions and a constitutive nuclear localiza-
tion of TFE3, independent of nutrient status (Fig EV5B, quantified
in EV5B’ and Appendix Fig S9C). These data show that the increase
in endolysosomal compartments and the mTORC1/TFE3 phenotype
is caused by a dysfunctional HOPS complex. We then studied the
effect of VPS41 or HOPS depletion on the canonical mTORC1
substrates S6K1 and 4EBP1, required for cellular growth. Intrigu-
ingly, phosphorylation of these substrates was not affected by the
absence of VPS41 or other HOPS subunits (Fig 5E, quantified in 5E’
and Fig EV5C). Likewise, phosphorylation of ULK1, another
substrate of mTORC1 involved in autophagy initiation, was not
affected in HOPS knockout cells (Fig EV5D). These data imply that
the HOPS complex selectively regulates the mTORC1-dependent
control of the MiT/TFE family of transcription factors.
We conclude from these data that VPS41 patient cells show a
decreased association of mTORC1 with lysosomes, a continuous
nuclear localization of TFE3, and increased expression of LC3II and
other CLEAR proteins. Notably, the autophagy defect is specific for the
patient-derived fibroblasts and not observed in any of the parental cell
lines. VPS41KO cells show a similar lysosomal dissociation of mTORC1
and constitutive nuclear localization of TFE3 whereas phosphorylation
of S6K1 and 4EBP1 is unaffected. This mTORC1/TFE3 phenotype is
HOPS dependent, since depletion of other HOPS subunits results in a
similar phenotype. The phenotype cannot be rescued by expression of
VPS41S285P or VPS41R662*, which is in line with our other findings
showing that these variants cannot restore HOPS function.
VPS41S285P allows for normal regulated secretion in PC12 cells
In secretory cells, VPS41 is required for secretory protein sorting
and secretory granule biogenesis in a pathway that is independent
of the HOPS complex (Asensio et al, 2013; Burns et al, 2020). This
VPS41 function requires the N-terminal residues 1–36 for interaction
with AP-3 and the presence of the C-terminal located CHCR domain
(Asensio et al, 2013; Margarita Cabrera et al, 2010). It was suggested
that VPS41 might form a coat on AP-3 containing membranes that
exit the TGN (Rehling et al, 1999; Darsow et al, 2001; Asensio et al,
2013). Since VPS41R662* lacks both the RING domain and part of the
CHCR domain, a function of this variant in regulated secretion is
prohibited (Asensio et al, 2013). However, VPS41S285P could theo-
retically still exert this HOPS-independent function. To test this, we
first investigated whether VPS41S285P can interact with AP-3. Pull-
downs of recombinant VPS41 constructs with the hinge-ear domain
of AP-3D1 showed that VPS41S285P binds AP-3 with equivalent affin-
ity as VPS41WT (Fig 6A and Appendix Fig S10).
To directly test the effect of VPS41S285P on regulated secretion,
we made use of PC12VPS41KO cells. By using EGF-ALEXA647 degra-
dation as readout, we established that these cells show a similar
endocytosis defect as patient fibroblasts and VPS41KO HeLa cells
(Appendix Fig S11A and B) and also display the HOPS-dependent
mTORC1/TFE3 phenotype (Fig EV4E). Regulated protein secretion
was measured as previously described (Asensio et al, 2010). Briefly,
cells were incubated in Tyrode’s buffer containing 2.5 mM (basal)
or 90 mM (stimulated) K+ and the supernatant and cell lysates were
analyzed by quantitative fluorescent immunoblotting (Fig 6B). As
previously shown, depletion of VPS41 from PC12 cells resulted in
decreased cellular SgII protein levels, as well as in a reduction in the
regulated secretion of the proteins that are present (Asensio et al,
2013). Reintroducing VPS41WT in PC12 VPS41KO cells rescued cellu-
lar SgII levels and recovered regulated secretion (Fig 6C and D).
Interestingly, similar results were obtained by expression of the
VPS41S285P variant (Fig 6C and D), indicating that its role in regu-
lated secretion has been preserved.
Together, these data show that expression of VPS41S285P rescues
the regulated secretory pathway in VPS41KO PC12 cells. Thus, the
VPS41S285P variant is defective in HOPS-dependent endocytosis and
autophagy pathways, but retains its HOPS-independent role in regu-
lated secretion.
Co-expression of VPS41S285 and VPS41R662* abolishes
neuroprotection in a C. elegans model of Parkinson’s disease
The clinical symptoms of the VPS41 patients (Fig 1) overlap with
Parkinson’s disease (Jankovic, 2008; Reich and Savitt, 2016). Previ-
ously, a screen for neuroprotective factors in a transgenic C. elegans
model for Parkinson’s disease showed that overexpression of
human VPS41 protects against a-synuclein-induced neurodegenera-
tion (Hamamichi et al, 2008; Ruan et al, 2010; Harrington et al,
◀ Figure 5. Patient fibroblasts and VPS41KO cells exhibit mTORC1 inhibition toward TFE3.
A Immunofluorescence of control, parental, and patient fibroblasts labeled for LAMP-1 and mTOR. In steady state conditions (0 h), VPS41S285P/R662* fibroblasts show less
colocalization between mTOR and LAMP-1. VPS41WT/WT, VPS41WT/S285P, and VPS41WT/R662* show an appropriate mTOR response upon nutrient deprivation (2 h) or
restimulation (2-h starvation followed by 15-min restimulation) (Appendix Fig S5A). > 10 Cells per cell line were quantified (A’). Quantifications are performed relative
to colocalization under steady state conditions per cell line (n = 3). Scale bars, 10 µm; zoom, 1 µm.
B Immunofluorescence of VPS41WT/WT, VPS41WT/S285P, VPS41WT/R662*, and VPS41S285P/R662* fibroblasts labeled for TFE3. In VPS41S285P/R662* fibroblasts, TFE3 is
constitutively localized in the nucleus regardless of nutrient state (quantified in B’). > 25 Cells per condition were quantified (n = 3). Scale bars, 10 µm.
C TFE3 immunofluorescence in HeLaWT and HeLaVPS41KO cells. In HeLaVPS41KO cells, TFE3 constitutively localizes in the nucleus (quantified in C’). > 83 Cells per condition
were quantified (n = 3). Scale bars, 10 µm.
D Rescue experiments of HeLaVPS41KO cells. Expression of VPS41WT-APEX2-V5, VPS41S285P-APEX2-V5, or VPS41R662*-APEX2-V5. Reintroduction of VPS41WT rescues TFE3
localization, whereas expression of mutant VPS41 has no effect (quantified in D’). > 83 Cells per condition were quantified (n = 3). Scale bars, 10 µm.
E Western blot of phosphorylated mTORC1 substrates S6K and 4EBP1 after starvation (2 h) and restimulation (10, 30 or 60 min). HeLaVPS41KO cells show comparable
levels of phospho-S6K and phospho-4EBP1, with no difference in recovery after restimulation (quantified in E’) (n = 3).
Data information: Data are represented as mean  SEM. *P < 0.05, **P < 0.01, ***P < 104, ****P < 105. One-way ANOVA with Bonferroni correction (A’–D’) or
unpaired t-test (E’). Exact P-values are reported in Appendix Table S3.
Source data are available online for this figure.
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2012). The neuroprotective effect of VPS41 depends on the presence
of the WD40 and CHCR domains and ability to interact with Rab7
and AP-3 (Harrington et al, 2012; Griffin et al, 2018). To explore the
impact of patient mutations in this Parkinson’s disease model, we
made transgenic nematodes, co-expressing the human VPS41
(hVPS41) variants found in patients 1 and 2. We crossed these with
isogenic strains overexpressing either GFP alone or human a-synu-
clein-GFP to mimic Parkinson’s disease.
First, we combined VPS41WT with VPS41S285P or VPS41R662*
expression, reflecting paternal and maternal conditions of patients 1
and 2, and studied if expression of these mutants induces neurode-
generation in the absence of a-synuclein. At 7 or 10 days post-hatching,
there was no statistically significant change in neurodegeneration
in any of these strains (Fig 7A and B). Likewise, when we co-expressed
VPS41S285P with VPS41R662* there was no discernable increase in
neurodegeneration. This demonstrates that co-expression of the
patient-specific VPS41 variants does not increase neurodegeneration in
(aging) animals.
We then analyzed VPS41 neuroprotective function in strains
overexpressing a-synuclein. At 7 days post-hatching, only ~43% of
the animal population overexpressing a-synuclein retains the full
complement of dopaminergic neurons and at 10 days only ~35%.
Previous studies show that expression of VPS41WT rescues neurode-
generation at day 7 and day 10, albeit it with reduced efficiency at
day 10 (Ruan et al, 2010; Harrington et al, 2012). Here, we found
that co-expression of VPS41WT with either VPS41S285P or VPS41R662*
significantly enhanced survival of dopaminergic neurons at day 7,
but at day 10 this protective effect was lost (Fig 7C and D). In
animals co-expressing VPS41S285P and VPS41R662*, reflecting patient
conditions, we found no protective effect at all at either day 7 or 10
(Fig 7C and D). Moreover, neurodegeneration at day 10 was signifi-


















































































Figure 6. VPS41S285P rescues regulated secretion in PC12 VPS41KO cells.
A Western blot of pulldown of AP-3 incubated with HIS-6 VPS41WT or VPS41S285P. There is no difference in affinity between VPS41WT and VPS41S285P (See
Appendix Fig S10 for MBP-AP-3 pulldown input).
B Western blot on cellular or secreted secretogranin II (SgII) of PC12 cells VPS41KO, or VPS41KO transduced with HA-VPS41WT or HA-VPS41S285P lentivirus. Cells were
washed and incubated for 30 min in Tyrode’s solution containing 2.5 mM K+ (basal) or 90 mM K+ (stimulated). No difference in secreted SgII levels was observed
between VPS41WT and VPS41S285P.
C, D Cellular (C) and secreted (D) secretogranin II (SgII) were measured by quantitative fluorescence immunoblotting (n = 3). VPS41S285P rescues intracellular SgII levels
and regulated secretion of SgII to the same extent as VPS41WT.
Data information: Data are represented as mean  SEM. *P < 0.05, **P < 0.01, ***P < 104. One-way ANOVA (C and D). Exact P-values are reported in
Appendix Table S3.
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variants adds additional stress besides a-synuclein overexpressing
and aging. Collectively, these data indicate that the capacity of
VPS41 to protect dopaminergic neurons against a-synuclein
overexpression is lost upon co-expression of the patient variants.
This implies that VPS41-mediated neuroprotection depends on the
HOPS complex.
Discussion
The vacuolar protein sorting-associated protein 41 (VPS41) has a
major contribution in vesicle-mediated trafficking to lysosomal
compartments including endocytic transport and the autophagic
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tethering complex which mediates fusion of lysosomes with late
endosomes and autophagosomes (Radisky et al, 1997; Nickerson
et al, 2009). Independently of the HOPS complex, VPS41 is involved
in the transport of lysosomal membrane proteins from the trans-
Golgi network (Pols et al, 2013b) and in regulated secretion of
neuropeptides (Asensio et al, 2013). Intriguingly, VPS41 was previ-
ously identified as neuroprotector in C. elegans and mammalian
models of Parkinson’s disease (Ruan et al, 2010; Harrington et al,
2012; Griffin et al, 2018). Here, we present three patients with a
neuronal disorder, bearing compound heterozygous variants in
VPS41 and show the consequences of this on the molecular and
cellular level. We demonstrate that all VPS41 variants give rise to a
non-functional HOPS complex and a kinetic defect in the delivery of
endocytic and autophagic cargo to enzymatically active lysosomes.
Most strikingly, we find that lack of HOPS function causes increased
dissociation of mTORC1 from lysosomes and the transfer of TFE3 to
the nucleus, resulting in continuously increased autophagy levels.
By contrast, phosphorylation of mTORC1 substrates S6K and 4EBP1
is not affected. Our studies thereby link HOPS complex functionality
to mTORC1 signaling, specifically for the TFEB/TFE3 axis.
Patients 1 and 2, two brothers, were diagnosed with global devel-
opmental delay, hypotonia, ataxia, and dystonia. By exome
sequencing, we identified a missense variant in the WD40 domain
(VPS41S285P) and a nonsense variant in the CHCR domain resulting
in a premature stopcodon (VPS41R662*). The third patient, present-
ing with severe developmental delay, axial hypotonia, and spastic
quadriplegia, was identified with a splice site variant in the TPR-like
domain (VPS41c.1423-2A>G) and the same nonsense variant in the
CHCR domain as observed in the siblings (VPS41R662*). By Western
blot, we found that only the VPS41S285P variant was expressed at
significant levels in patient fibroblasts. The truncated VPS41R662*
form could not be detected at all, whereas expression levels of
VPS41c.1423-2A>G were strikingly low. Hence, cells from patients 1
and 2 only contained the VPS41S285P variant, whereas patient 3 only
contained VPS41c.1423-2A>G at about 10% of wild-type VPS41 levels
which could explain the more severe phenotype observed in patient
3. The three patients described here share features with a recently
reported patient bearing a homozygous VPS41 splice site variant
(NM_014396.3c.450 + 1G>T) (Steel et al, 2020). All patients show
the autosomal recessive inheritance pattern, early onset generalized
dystonia with developmental delay, and brain MRI characterized by
thinning of the corpus callosum and atrophy of the cerebellar
vermis. One of our patients (Patient 1) presents a slightly different
phenotype, characterized by a less severe intellectual disability and
ataxia without overt dystonia, clearly indicating that the phenotypic
expression of VPS41-related disorders is variable.
Since VPS41S285P is the only variant expressed at substantial
levels, we investigated whether it could form a functional HOPS
complex. By co-IPs using tagged constructs, we found that
VPS41S285P interacts with other HOPS subunits and by immunofluo-
rescence that this variant is recruited to endolysosomal membranes.
However, expression of VPS41S285P in VPS41KO HeLa cells did not
rescue the HOPS-dependent fusion between lysosomes and late
endosomes or autophagosomes. Since a serine to proline substitu-
tion is predicted to affect protein folding, the inability of VPS41S285P
to form a functional HOPS complex may be due to a folding defect.
Importantly, these data demonstrate that all patient variants affect
HOPS function, either because of lack of expression and/or an
inability to form a functional complex. In accordance, HOPS-depen-
dent transport of endocytosed Dextran to enzymatically active lyso-
somes is significantly decreased in patient cells as compared to the
healthy controls. Intriguingly, the VPS41WT/R662* cells of the mother
of the two siblings also showed decreased delivery to lysosomes.
This effect was apparent after 2 h Dextran incubation but disap-
peared after 5 h. By contrast, lysosomal delivery in patient cells
reached control levels only after 24 h uptake. This shows that
expression of the VPS41 variants causes a delay rather than a block
in HOPS-dependent transport to lysosomes and implies that the
kinetics of cargo delivery to lysosomes is a factor of importance in
the development of VPS41-associated pathology.
Independent of HOPS, VPS41 is also required for formation of
secretory granules and transport of lysosomal membrane proteins
via the ALP/LAMP-carrier pathway (Cowles et al, 1997b; Darsow
et al, 2001; Swetha et al, 2011; Pols et al, 2013b). Both functions
were reported to depend on the interaction of VPS41 with AP-3
(Cowles et al, 1997a; Rehling et al, 1999; Darsow et al, 2001;
Angers & Merz, 2009; Cabrera et al, 2010). By co-IP, we found that
VPS41S285P still binds AP-3 with an affinity comparable to VPS41WT.
By immuno-EM of patient-derived fibroblasts, we found no effect on
the concentration of LAMP-1 or LAMP-2 in lysosomal membranes.
Also, cathepsin B and cathepsin D were readily transported to and
activated in lysosomes. Though these steady state assays do not give
information on transport kinetics, they do indicate that lysosomes
in patient cells contain normal levels of lysosomal proteins.
◀ Figure 7. Compound heterozygous expression of hVps41 variants fails to rescue a-synuclein-induced neurodegeneration in C. elegans.
A Graph representing the percentage of adult C. elegans animals with 6 normal dopaminergic neurons. Heterozygous expression with hVPS41WT (strains UA386 or
UA387) or compound heterozygous expression of hVPS41 variants (strain UA388) does not yield significant changes in neurodegeneration compared with the Pdat-1::
GFP (strain BY250) control at either day 7 or day 10 post-hatching. n = 30 Adult worms for each of 3 independent experiments for GFP (total of 90 worms) and
n = 90 for each independent transgenic strain (30 worms/trial × 3 independent transgenic lines = 270 worms), for each of 3 independent experiments.
B Representative images of the neuroprotection assay described in (A), where worms express GFP specifically in the anterior 6 DA neurons. Intact DA neurons are
indicated with arrowheads. hVPS41 variant backgrounds are expressed as indicated. Scale bar 20 µm.
C Graph representing the percentage of animals with 6 normal dopaminergic neurons in the anterior region of Pdat-1::GFP; Pdat-1:: a-syn (strain UA44) animals with
heterozygous expression of hVPS41 variants. Heterozygous expression of hVPS41WT with either variant (strains UA389 or UA390) significantly rescues neurons from a-
synuclein-induced degeneration at day 7 whereas compound heterozygous expression (strain UA391) fails to rescue neurodegeneration. At day 10, none of the
heterozygous backgrounds significantly rescues a-synuclein-induced neurodegeneration. n = 30 Adult worms for each of 3 independent experiments for the a-
synuclein (a-syn) strain (total of 90 worms) and n = 90 for each independent transgenic strain (30 worms/trial × 3 independent transgenic lines = 270 worms) for
each of 3 independent experiments.
D Representative images of DA neurons from C. elegans expressing Pdat-1::GFP; Pdat-1:: a-syn, with or without hVPS41 variants, as described in (C). Intact DA neurons are
indicated with arrowheads and missing neurons are indicated with arrows. Scale bar 20 µm.
Data information: Data are represented as mean  SD. *P < 0.05. One-way ANOVA with Tukey’s correction (A and C). Exact P-values are reported in Appendix Table S3.
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Interestingly, we found that expression of VPS41S285P fully rescued
the secretion defect in VPS41KO PC12 cells. Likewise, in a parallel
study we found that expression of VPS41S285P in VPS41KO INS-1 cells
restored insulin secretion (Burns et al, 2020). This shows that
expression of VPS41S285P fails to restore HOPS function, but does
rescue the regulated secretion pathway in PC12 and INS cells. It is
conceivable that this activity of VPS41S285P in secretion is important
for disease development, but how exactly VPS41 regulates secretion
—direct or indirect?—remains to be elucidated. In future studies, we
can use the VPS41S285P variant to distinguish between these HOPS-
dependent and HOPS-independent functions of VPS41.
A striking finding in our studies is that expression of the VPS41
variants leads to a decreased lysosomal localization of mTORC1, a
constitutive nuclear localization of TFE3, and impaired TFEB phos-
phorylation. This was seen in patient-derived fibroblasts and reca-
pitulated in HeLa and PC12 cells knockout for VPS41, indicating
that this phenotype occurs across different cell types. TFE3 and
TFEB are part of the MiTF/TFE family of transcription factors (Slade
& Pulinilkunnil, 2017). Both TFE3 and TFEB translocate to the
nucleus upon nutrient starvation and bind CLEAR elements in
promotors of autophagic and lysosomal genes (Sardiello et al, 2009;
Palmieri et al, 2011). In VPS41 disease cells, the continuous nuclear
localization of TFE3 results in elevated levels of target genes like
LAMP-1 and cathepsin B, which is in agreement with the observed
increase in number of small-sized, LAMP-1-positive compartments.
Even though lysosomal size is controlled by a diversity of pathways
(de Araujo et al, 2020), we speculate that due to HOPS complex
dysfunctionality and subsequent impaired fusion between endolyso-
somal compartments, these newly formed organelles remain small
because of decreased membrane input, as is observed in both
patient and VPS41KO cells.
It is tempting to speculate that impaired endocytic cargo delivery
deprives lysosomes of nutrients, thereby causing a state of starva-
tion. However, phosphorylation of S6K and 4EBP1, canonical
substrates of mTORC1, was not affected in cells depleted of a func-
tional HOPS complex. Indeed, also VPS18KO and VPS39KO cells
showed constitutive nuclear localization of TFE3, but normal S6K
and 4EBP1 phosphorylation in response to nutrient starvation and
replenishment. Also, phosphorylation of ULK1 was not affected in
any of the knockout cells. These findings suggest that HOPS-defi-
cient cells are not continuously starved or impaired in nutrient sens-
ing, but that the HOPS complex specifically regulates mTORC1-
dependent control of the TFEB/TFE3 axis. Interestingly, cells
depleted of Folliculin (FLCN), the GTPase activating protein (GAP)
for the lysosome-associated RagC/D GTPases necessary for
membrane recruitment of mTORC1, are also selectively affected in
the TFEB/TFE3 axis, with no effect on S6K and 4EBP1 phosphoryla-
tion (Lawrence et al, 2019). As explanation for a differential regula-
tion of mTORC1 substrates, it was recently proposed that amino
acids, and not growth factors, are required for FLCN-mediated regu-
lation of TFEB/TFE3 (Napolitano et al, 2020). Possibly the HOPS
complex, by facilitating late endosome–lysosome fusion, is required
for the delivery of degradable material for the supply of amino
acids. This endolysosomal fusion might not be necessary for the
growth factor-dependent regulation of S6K/4EBP1. Indeed, cells
treated with chloroquine, which recently was shown to block late
endosome–lysosome fusion, also show translocation of TFE3 to the
nucleus (Roczniak-ferguson et al, 2012; Mauthe et al, 2018).
Additionally, HOPS could be involved in the association of mTORC1
and/or TFEB/TFE3 with lysosomes. TFEB/TFE3 and mTORC1 both
bind to active Rags on the lysosomal membrane, thereby enabling
the phosphorylation of TFEB/TFE3 (Martina & Puertollano, 2013).
By contrast, S6K and 4EBP1 do not associate with the lysosomal
membrane and, therefore, lysosomal association of mTORC1 is less
crucial for phosphorylation of these latter substrates (Napolitano
et al, 2020). Since patient and VPS41KO cells show decreased associ-
ation of mTORC1 with the lysosomal membrane, an interesting
hypothesis is that the HOPS complex enables lysosomal association
and retention of mTORC1 and TFE3/TFEB, possibly by cooperating
with the Rags.
Currently, patients with mutations in HOPS core components
VPS11, VPS16, VPS33A, and VPS41 have been reported in literature,
which all show a neurodegenerative phenotype (Chintala et al,
2009; Edvardson et al, 2015; Zhen & Li, 2015; Cai et al, 2016;
Hörtnagel et al, 2016; Kondo et al, 2016; Zhang et al, 2016; Dursun
et al, 2017; Beek et al, 2019; Pavlova et al, 2019; Steel et al, 2020).
During our studies, an additional patient with a homozygous splice
site variant (NM_014396.3c.450 + 1G>T) in VPS41 was identified,
displaying a neurological phenotype similar to the patients
discussed here (Steel et al, 2020). For future studies, it will be inter-
esting to obtain cells from this patient and screen for the mTORC1/
TFE3 phenotype.
VPS41 was previously reported to confer neuroprotection in both
C. elegans and mammalian models for Parkinson’s disease (Hama-
michi et al, 2008; Ruan et al, 2010; Harrington et al, 2012; Griffin
et al, 2018). Overexpression of a-synuclein results in degeneration
of dopaminergic neurons, which is prevented by overexpression of
human VPS41. Both the WD40 and CHCR domain of VPS41 are
necessary for this neuroprotection (Ruan et al, 2010; Harrington
et al, 2012), which are mutated in VPS41S285P and VPS41R662*,
respectively. We found that transgenic nematodes co-expressing
hVPS41WT with either VPS41S285P or VPS41R662*retained the neuro-
protective effect, resulting in a decrease in neurodegeneration.
However, co-expressing VPS41S285P and VPS41R662* did not result in
neuroprotection and even exacerbated cell death in aging worms.
Since we found that the VPS41 patient cells completely lack HOPS
function, the neurodegenerative phenotype in the nematodes is
likely HOPS related. Moreover, since HOPS-dependent autophago-
some–lysosome fusion is important for clearance of aggregated
material, which particularly tends to accumulate in neurons over
the course of aging (Takats et al, 2009; Jiang et al, 2014; McEwan
et al, 2015; Jia et al, 2017), overexpression of VPS41 in the
C. elegans model possibly induces protein clearance through autop-
hagy. The intersection of lysosomal dysfunction and neurodegenera-
tion has become a critical junction in the mechanistic underpinnings
of Parkinson’s disease (Mazzulli et al, 2011). This is best exempli-
fied by mutations in the gene encoding the lysosomal protein GBA1,
which causes Gaucher’s disease and has become the most prevalent
genetic risk factor for Parkinson’s disease (Do et al, 2019). In the
context of these results, it is tempting to speculate that an increased
understanding of autolysosomal trafficking defects in VPS41 patient
cells may serve to inform therapeutic strategies for neurodegenera-
tive disorders (Griffin et al, 2018).
In summary, our data imply that VPS41 patients may represent a
novel class of lysosomal disorders in which lysosomes are enzymat-
ically active, but due to delayed trafficking kinetics inefficiently
18 of 24 EMBO Molecular Medicine 13: e13258 | 2021 ª2021 The Authors
EMBO Molecular Medicine Reini EN van der Welle et al
reached by endocytic and autophagic cargo. Moreover, patient cells
are selectively inhibited in mTORC1-mediated TFEB/TFE3 regula-
tion. Interestingly, many other neurodegenerative diseases show an
opposite phenotype, i.e., with hyperactivity of mTORC1 (An et al,
2003; Wong, 2013; Lam et al, 2017). These observations are of
particular importance with regard to the design of a possible treat-
ment of VPS41 and other HOPS-related disorders (Chintala et al,
2009; Laplante & Sabatini, 2012; Wong, 2013; Dursun et al, 2017;
Pavlova et al, 2019).
Materials and Methods
Patient material and identification of VPS41 variants
Informed consent was obtained from all subjects and the experi-
ments conformed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human Services
Belmont Report. Parents provided written informed consent for
publication of clinical pictures. Information about whole exome
sequencing, filtering, and variant analysis is presented in
Appendix Supplementary Methods.
Antibodies, reagents, and lysosomal functionality assays
Antibodies and reagents used in this study and their specific dilu-
tions or used concentrations are specified in Appendix Table S2. To
study endocytosis, cells were incubated for 2 h with 10,000 MW
Dextran-Alexa Fluor 568 (Invitrogen), washed five times using warm
PBS, fixed with 4% PFA, embedded in Prolong DAPI (Invitrogen),
and imaged. Lysosomal acidity was determined using LysotrackerTM
Red (Molecular Probes) for 30 min after which cells were washed
five times using 37°C PBS, fixed with 4% PFA, embedded in
Prolong DAPI (Invitrogen), and imaged. To visualize active lyso-
somes, we used the SiR-Lysosome (Spirochrome) probe. Cells were
incubated for 3 h, washed with PBS, fixed with 4% PFA, embedded
in Prolong DAPI (Invitrogen), and imaged. For the visualization of
cathepsin B-active compartments, cells were incubated with
MagicRed cathepsin B substrate (Molecular Probes) for 30 min and
imaged at RT using live-cell imaging. To assess EGF degradation,
WT and VPS41KO PC12 cells were washed twice with PBS and
starved of serum for 2 h in DMEM with 0.1% BSA (GoldBio).
During starvation, EGF-biotin (GoldBio) streptavidin-647 conjugate
was prepared. EGF-biotin (5 lg/ml) was incubated for 30 min at
4°C at a 5:1 ratio to streptavidin-Alexa647 (Life Technologies).
Following starvation, cells were washed twice with ice-cold PBS on
ice and incubated with EGF-A647 conjugate at a final concentration
of 100 ng/ml for 1 h on ice. Excess unbound EGF was removed by
washing with ice-cold PBS with 0.5% BSA. Cells were chased for
indicated times at 37°C before fixation with 4% PFA in PBS for
20 min at room temperature. Cells were analyzed by flow cytometry
(CyAn ADP Analyzer, Beckman Coulter, USA) or scanning confocal
microscopy.
For the RT–PCR, mRNA was isolated from cells using RNeasy kit
(Qiagen) and converted to cDNA using TaqMan reverse transcrip-
tase reagents (Applied Biosystems). Real-time PCR was performed
using PCR mastermix with SYBR green (Applied Biosystems) with
primers that were ordered from realtimeprimers.com.
Cell culture and light and electron microscopy
Patient-derived fibroblasts and HeLa cells were cultured in High
Glucose Dulbecco’s Modified Eagle’s Medium (Invitrogen) supple-
mented with 10% FCS in a 5% CO2-humidified incubator at 37°C.
Cells were transfected using X-tremeGENETM HP (Roche) according
to manufacturer’s instructions. To induce autophagy, cells were
starved for 2 h at 37°C using EBSS (Thermo Fisher) and restimulated
for 15 min with complete medium. Cells destined for immunofluo-
rescence were washed with PBS once and fixed using 4% wt/vol
paraformaldehyde (PFA, Polysciences Inc.) for 20 min. Cells were
washed three times with PBS and permeabilized with 0.1% Triton
X-100 (Sigma) for 5 min. Samples were blocked for 15 min using a
1% BSA solution. Samples were labeled, embedded in Prolong DAPI
(Invitrogen), and imaged. When imaging transfected cells, cells with
similar transfection levels were selected. Images were taken using a
Deltavision wide-field microscope (Applied Precision) with a 100x/
1.4A oil immersion objective. Image analysis was performed using
Volocity software (Perkin Elmer) and macros written in Fiji (Schin-
delin et al, 2012). The ComDet plugin was used for dot detection for
quantifications of immunofluorescent images (Eugene Katrukha,
Utrecht University). For TFE3 localization experiments, cells were
scored positive when a defined nuclear outline was visible due to
nuclear labeling of TFE3.
For resin EM, cells grown in 6cm dishes were fixed in 2% wt/vol
PFA, 2.5% wt/vol GA (Electron Microscopy Sciences) in Na-cacody-
late buffer (Karnovsky fixative) for 2 h at RT. Subsequently, the fix-
ative was replaced for 0.1 M Na-cacodylate buffer, pH 7.4. Post-
fixation was performed using 1% wt/vol OsO4, 1.5% wt/vol K3Fe
(III)(CN)6 in 0.065 M Na-cacodylate buffer for 2h at 4°C. Next, cells
were stained with 0.5% uranyl acetate for 1 h at 4°C, dehydrated
with ethanol, and embedded in Epon (Electron Microscopy
Sciences). Ultrathin sections were stained with uranyl acetate and
lead citrate using AC20 (Leica). Images were taken on a TECNAI
T12 electron microscope (FEI Thermo Fisher Scientific).
For immuno-EM, cells were grown in 6cm dishes were incubated
with BSA-Au5 (Cell Microscopy Core, UMC Utrecht) for 2h in culture
medium at 37°C, washed with medium, and fixed by adding freshly
made 2% FA, 0.2% GA in 0.1 M phosphate buffer (pH 7.4) to an
equal volume of medium for 15 min. After 15 min, the fixative was
refreshed to continue fixation for 2h at RT. Cells were stored in 1%
formaldehyde at 4°C until further processing. Then, cells were
washed with PBS/0.05 M glycine, scraped in 1% gelatin/PBS,
pelleted in 12% gelatin/PBS, solidified on ice, and cut into small
blocks. The blocks were infiltrated in 2.3 M sucrose overnight at
4ᵒC, mounted on aluminum pins, and frozen in liquid nitrogen (Slot
& Geuze, 2007). Ultrathin sections were prepared using an ultra-
cryomicrotome (Leica). To pick up ultrathin sections, a 1:1 mixture
of 2.3 M and 1.8% wt/vol methylcellulose was used. Ultrathin
sections were immuno-gold labeled and stained as described (Slot &
Geuze, 2007). Protein A-conjugated colloidal gold particles were
made in house (Cell Microscopy Core, UMC Utrecht).
CRISPR/Cas9 knockout cells
HeLaVPS41KO
Hela cells were transiently transfected with pSpCas9(BB)-2A-GFP
(PX458) (Ran et al, 2013) encoding sgRNAs targeting VPS41 using
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X-tremeGENE (Merck) according to the manufacturers recommenda-
tion. sgRNAs were designed with http://crispor.tefor.net/ (Haeus-
sler et al, 2016) and target coding sequences in the N-terminal
region encoded by the third coding exon. The sgRNA used is sgRNA2
AAGTATTTCAGTTACCCCAT. GFP-positive cells were sorted using a
FACSAria II flow cytometer (BD) and plated in 10-cm dishes. Colo-
nies were picked from these plates after 1 week and expanded. To
confirm VPS41 absence, total cell lysates were analyzed by Western
blotting using mouse anti-VPS41 (SC-377271, Santa Cruz).
HeLaVPS11KO/VPS18KO/VPS39KO
To generate VPS11, VPS18, and VPS39 knockout HeLa cells, a WT
HeLa parental stain was transfected with pSpCas9(BB)-2A-Puro
(PX459) plasmids containing gsRNAs for VPS11, VPS18, or VPS39
using Effectene transfection reagent (QIAGEN). gsRNAs were
designed using against the first exons of VPS11, VPS18, and
VPS39 using an optimized CRISPR design tool. sgRNA sequences
that generated the knockout cells used in this study were GTG
TGTCACCCGTAGTTTGT for VPS11, CGAGAACTCGCTGTCCCGCT
for VPS18, and GCCTCTGCAAATCGACTGTC for VPS39. We selected
for transfected cells using 1 µg/ml Puromycin. Surviving cells were
recovered for 2 weeks and split into 96-well plates at single cell/
well dilution. Single cell colonies were selected and expanded. For
VPS18 and VPS11 clones, knockout was confirmed by the absence
of VPS18 or VPS11 protein on Western blot. VPS39 knockout
clones were confirmed via genomic DNA isolation followed by
PCR of VPS39 exon 1, sequencing, and analysis using the TIDE
sequence analysis tool (https://tide.nki.nl/). The selected VPS39
knockout clone had two deletions of 5 and 8 nucleotides in the first
exon, resulting in a frameshift.
PC12VPS41KO
The human codon-optimized Cas9 and chimeric guide RNA expres-
sion plasmid (pX459v2) developed by the Zhang laboratory were
obtained from Addgene (Ran et al, 2013). To generate gRNA plas-
mids, a pair of annealed oligos (20 base pairs) were ligated into the
single guide RNA scaffold of pX459v2. The following gRNAs
sequences were used: Forward (rat): 50-CACCGACTCTCAGACT
GAGCTATGG-30; Reverse (rat): 50-AAACCCATAGCTCAGTCTGA
GAGTC-30 to generate the PC12VPS41KO line. Rat VPS41 lentiviral
plasmid was generated by amplifying VPS41 from rat cDNA using
the following primers: WT Forward: 50-CCTCCATAGAAGACAC
CGACTCTAGACACCATGGCGGAAGCAGAGGAG-30; WT Reverse:
50-TATGGGTAACCCCCAGATCCACCGGTCTTCTTCATCTCCAGGAT
GGCA-30. The PCR products were then subcloned by Gibson ligation
into pLenti-CMV-GFP-Puro. pLenti-CMV-GFP-Puro was a gift from
Paul Odgren (Addgene plasmid #73582). To test for the presence of
indels, the resulting PCR products were ligated into pBlueScript II
KS. Isolated plasmids from 10 random colonies were analyzed for
the presence of indels by Sanger sequencing. Insertions in the initia-
tor codon of the VPS41 gene were observed in all clones of either a
single or a triple T.
Co-immunoprecipitation and Western blotting
Cells were seeded in 15-cm dishes and transfected with the appro-
priate constructs as indicated in the respective figures and according
to abovementioned transfection protocols. Cells were washed three
times with ice-cold PBS and lysed using a CHAPS lysis buffer
(50 mM Tris pH = 7.5, 150 mM NaCl, 5 mM MgCl2, 1mM DTT, 1%
(w/v) CHAPS) complemented with protease and phosphatase inhi-
bitor (Roche). Cells were scraped, collected, and spun down at
16,000 rcf/g for 15 min at 4°C. Protein levels were equalized
between samples using a Bradford Protein Assay (Bio-Rad). 10% of
the sample was saved as input control. The remainder of the
samples was incubated for 1 h with uncoated protein G beads (Milli-
pore) to remove a-specifically bound proteins. Beads were spun
down and the supernatant was incubated with beads together with
2 µg antibody against the prey. Samples were incubated overnight,
extensively washed, and eluted using SDS sample buffer and run on
precast gradient (4–20%) gels (Bio-Rad). Gels were transferred
using Trans-Blot TurboTM RTA Mini PVDF Transfer Kit and the
Trans-Blot TurboTM Transfer system (Bio-Rad). Membranes were
blocked with Odyssey Blocking Buffer (LI-COR) in PBS for 1h at
RT and incubated with primary antibody diluted in Odyssey Block-
ing Buffer (LI-COR) in 0.1% TBST overnight at 4°C, rocking.
Membranes were washed extensively with 0.1% TBST and incu-
bated with secondary antibodies, diluted in Odyssey Blocking Buf-
fer (LI-COR) in 0.1% TBST at RT for 1 h, rocking. The membranes
were again washed extensively with 0.1% TBST, followed by 2
washing steps with PBS and 1 washing step with MiliQ. Membranes
were scanned using the AmershamTM TyphoonTM Laser Scanner (GE
Healthcare Life Sciences).
Plasmids
The GFP-VPS41 constructs were cloned from hVPS41 cDNA (Ori-
gene) into a pDonor201 vector (Invitrogen) using PCR. Next, using
the Gateway system and GFP-pcDNA-Dest53 (kindly provided by
Prof. R. Roepman, Radboud University Medical Center Nijmegen), a
recombination reaction was performed. The VPS41 mutant variants
were made using the QuickChange Site-Directed Mutagenesis kit
(Agilent) using the primers 5’-CAGCTTGTTGTACTTCCGTATGT
AAAGGAGA and 5’-TCTCCTTTACATACGGAAGTACAACAAGCTG
to generate GFP-VPS41S285P and 5’-GTTTATCTTCTGAGCTGAATG
GGTTAATAGCC and 5’-GGCTATTACCCATTCAGCTCAGAAGATA
AAC to generate GFP-VPS41R662*. The pcDNA3-APEX2-V5 construct
(kindly provided by Dr. S. de Poot) was used as empty vector in
pulldown experiments. VPS41-APEX2-V5 was generated via a
BamHI insert using pEGFP-C1-mCherry-VPS41 (kindly provided by
Prof. J.J.C. Neefjes, University Medical Center Leiden) using
the primers 5’-AGAGGGATCCATGGCGGAAGCAGAGGAGCAG and
5’-AGAGTCTAGACTATTTTTTCATCTCCAAAATTG. VPS41S285P-APEX2-V5
and VPS41R662*-APEX2-V5 were generated via an identical approach
using pEGFP-C1-mCherry-VPS41S285P and pEGFP-C1-mCherry-
VPS41R662*. These VPS41 variants were made using the abovemen-
tioned Mutagenesis kit (Agilent) and the same primer pairs.
For the C. elegans experiments, the wild-type (wt) Pdat-1::hVPS41
construct was assembled as previously described (Harrington et al,
2012). Briefly, human VPS41 cDNA was obtained from Open Biosys-
tems (Huntsville, AL). Plasmid entry vectors were generated using
Gateway Technology (Invitrogen) to clone PCR amplified constructs
into pDONR221 to generate a hVPS41 entry clone. The hVPS41
entry clone was used to clone hVPS41 into the Gateway expression
vector, pDEST-Pdat-1. The mutant hVPS41 alleles were generated by
site-directed mutagenesis of the Pdat-1::hVPS41 construct using the
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TCACAGAGAGGTGCAAGTCCACTGATGTAGAAT to generate the
Pdat-1::hVPS41





to generate the Pdat-1::hVPS41
R662* construct. The identities of
the Gateway entry and expression constructs were validated by
DNA sequencing.
Caenorhabditis elegans strains
Transgenic C. elegans strains were generated by directly injecting a
Punc-54::tdTomato co-injection marker (50 ng/µl) and Pdat-1::hVPS41
wt (25 ng/µl) with Pdat-1::hVPS41
S285P (25 ng/µl) or Pdat-1::
hVPS41R662* (25 ng/µl) constructs or Pdat-1::hVPS41
S285P (25 ng/µl)
with Pdat-1::hVPS41
R662* (25 ng/µl) into the gonads of strain N2 Bris-
tol hermaphrodites. Progeny of injected animals were screened for
expression of the hVPS41 expression constructs by evidence of fluo-
rescence in the body-wall muscles from the Punc-54::tdTomato co-
expression marker. Several stable lines of each were isolated and
crossed with isogenic UA44 (baIn11[Pdat-1::a-syn, Pdat-1::GFP]) and
BY250 (vtIs7[Pdat-1::GFP]) males. Heterozygous hermaphroditic
progeny expressing both tdTomato and GFP were transferred and
allowed to self-fertilize. Several lines of each Pdat-1::hVPS41wt + Pdat-
1::hVPS41
S285P [baEx215] in UA44 (UA389) and BY250 (UA386) were
analyzed for neurodegeneration at days 7 and 10. Likewise, Pdat-1::
hVPS41wt + Pdat-1::hVPS41
R662*[baEx216] in UA44 (UA390) and
BY250 (UA387) was analyzed. Additionally, Pdat-1::hVPS41
S285P + Pdat-1::
hVPS41R662* (baEx217] in the UA44 (UA391) or BY250 (UA388) back-
grounds was analyzed. For all strains, three representative lines of each
were selected for further analysis.
Dopaminergic neurodegeneration analysis in
Caenorhabditis elegans
Caenorhabditis elegans dopaminergic neurons were analyzed for
degeneration as previously described (Hamamichi et al, 2008;
Harrington et al, 2012). Briefly, synchronized progeny from the
BY250, UA44, and experimental hVPS41 variant strains were
produced from a 3-h egg-lay and grown at 20°C. Animals were
analyzed at days 7 and 10 post-hatching (4- and 7-day-old adults).
On the day of analysis, the 6 anterior dopaminergic neurons [4 CEP
(cephalic) and 2 ADE (anterior deirid)] were examined in 30 adult
hermaphrodite worms, which were immobilized on glass cover slips
using 3 mM levamisole and transferred onto 2% agarose pads on
microscope slides. In quantifying neurodegeneration, animals are
scored as “normal” when a full complement of all 6 anterior
dopaminergic neurons are present and the neuronal processes are
fully intact, as previously reported (Cao et al, 2005; Hamamichi et
al, 2008; Harrington et al, 2010). In total, at least 90 adult worms
(30 worms/trial × 3 trials = 90 total animals) were analyzed for
each independent strain and at least 270 adult worms were analyzed
for each independent transgenic strain (30 worms/trial × 3
independent transgenic lines × 3 trials = 270 total animals/con-
struct). Values of each independent experiment were normalized to
the BY250 control, and representative analyses were averaged and
statistically analyzed by Prism and one-way ANOVA.
Protein purification
The appendage domain of rat AP-3 delta was amplified by PCR and
cloned in-frame into pET15b-MBP-MCS. The recombinant proteins
were induced overnight at 20°C in Escherichia coli BL21 (DE3) using
0.1 mM IPTG. The bacteria were lysed by sonication in in 50 mM
Tris, 300 mM NaCl, pH 8.0, and MBP fusions purified by incubation
with amylose resin beads (NEB) and eluted with 50 mM maltose in
50 mM Tris, 300 mM NaCl, pH 8.0. Two days after infection with
baculoviruses produced according to the manufacturer’s instruc-
tions (Invitrogen), Hi5 cells were harvested by centrifugation and
resuspended in binding buffer (50 mM Tris, 300 mM NaCl, pH 8.0)
with 1 mM PMSF and protease inhibitors (Complete, Roche). The
cells were lysed by sonication and pelleted for 20 min at 21,000 g
using a 4°C Eppendorf 5424 centrifuge. Supernatant was passed
through a 0.2 lm filter and incubated with Co-Nta agarose
(GoldBio) for 1 h at 4°C. The agarose was then washed five times in
binding buffer with 10–40 mM imidazole and His-hVPS41 eluted
with 500 mM imidazole. The eluates were immediately desalted on
a Secadex-5 column (Prometheus) into lysis buffer. 50 lg of MBP or
MBP-AP-3 were loaded onto amylose resin for 30 min at 4°C.
Unbound protein was removed by several washing steps, and vary-
ing amounts of VPS41 were incubated with the MBP resin to assess




VPS41 is, as part of the HOPS complex, required for lysosomal fusion
events. Independently of HOPS, VPS41 is required for formation of
secretory granules. VPS41 prevents degeneration of dopaminergic
neurons overexpressing the Parkinson’s disease-related protein a-
synuclein. Here, we present three patients bearing compound
heterozygote mutations in VPS41 displaying a severe neurological
disorder. We address the question how these mutations affect endo-
cytosis, autophagy, secretory pathways, and neuroprotection.
Results
We show that mutations in or depletion of VPS41 causes a delay in
HOPS-dependent endocytic and autophagic cargo delivery to enzy-
matically active lysosomes and that neuroprotection against a-synu-
clein is reduced. Moreover, the disease-causing mutations specifically
impair mTORC1 activity toward TFE3 and TFEB, causing constitutive
activation of these transcription factors. As a result, lysosomal biogen-
esis and autophagosome formation is continuously upregulated inde-
pendent of nutrient conditions. By contrast, HOPS-independent
function of VPS41 in secretory transport is preserved.
Impact
Our study shows that VPS41 patients represent a new class of lysoso-
mal disorders in which lysosomes are functional, but insufficiently
reached by cargo due to a trafficking defect. Besides this, we show
that VPS41, as part of the HOPS complex, is involved in the differen-
tial regulation of mTORC1 toward TFE3/TFEB, which is of potential
importance for treatment of HOPS-related disorders.
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Secretion assays
PC12 cells were plated on poly-L-lysine, washed, and incubated in
Tyrode’s buffer containing 2.5 mM K+ (basal) or 90 mM K+ (stimu-
lated) for 30 min at 37°C. The supernatant was collected, cell lysates
prepared as previously described (Asensio et al, 2010), and samples
were analyzed by quantitative fluorescence immunoblotting.
Statistics
Quantification of all Western blots was performed using Fiji soft-
ware (Schindelin et al, 2012). Two-tailed Students t-tests were
performed to compare two samples whereas ANOVA was performed
for comparison of multiple samples to analyze statistical signifi-
cance. Data distribution was assumed to be normal, but this was
not formally tested. All error bars represent the Standard Error of
the Mean (SEM) or Standard Deviation (SD) as indicated in the
specific figure legends.
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
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